NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced a strategic alliance with DermEbx™ to offer the Xoft® Axxent® Electronic Brachytherapy System® to treat non-melanoma skin cancer (NMSC) throughout the DermEbx network of dermatology centers. DermEbx currently services 14 locations in Arizona, California and Nevada with Xoft System units placed in all locations.
“We are pleased to provide patients diagnosed with non-melanoma skin cancer this innovative and effective treatment option that is administered in their dermatologist’s office under the supervision of a radiation oncologist,” said Ken Ferry, iCAD’s CEO. “Electronic brachytherapy is a proven, non-invasive alternative to surgery, and this strategic alliance will allow us to expand the number of systems we have in place to treat more patients at centers managed by DermEbx. This agreement provides patients with a proven, convenient treatment alternative in a familiar care environment.”
“We are excited to bring the Xoft System to our managed centers as part of this strategic alliance,” said Kamal Gogineni, President of DermEbx. “The collaboration between DermEbx, dermatologists and its affiliated radiation oncologists will help create a comprehensive solution for this advanced technology in treating skin cancer patients.”
“DermEbx integrates the mobile Xoft System into its dermatology centers by allowing treatment to occur in the facility where the diagnosis is made, potentially eliminating the need to visit multiple service providers at different locations,” said David Berman, M.D., Medical Director, Berman Gladstone Skin Institute. “The mobility of the Xoft System enables a radiation oncologist to treat more patients at multiple dermatology centers.”
About Non-Melanoma Skin Cancer
NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is not only the most common type of skin cancer, it is the most common type of cancer in humans. These cancers commonly appear on sun-exposed areas of the body such as the face, ears, neck, lips and backs of the hands. NMSC affects approximately 2.2 million Americans each year.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early stage breast cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com.
Founded in January 2013, DermEbx is a leading healthcare services and technology company dedicated to offering skin electronic brachytherapy programs to Dermatology and Oncology Networks. This program includes collaboration with clinical care teams and management staff in successfully integrating equipment and software into a patient-centric workflow model. DermEbx helps its customers with scalability and operational efficiencies in delivering programs that meet quality and standards for improved patient care. For more information, call 408-625-7710 or visit www.dermEbx.com.
About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer, cervical cancer and endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the Company’s ability to identify a replacement for the Axxent FlexiShield Mini, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.